Astel­las pur­sues ‘con­vert­ible’ in vi­vo CAR-T cell ther­a­pies with Kelo­nia Ther­a­peu­tics

Astel­las is pen­ning a deal with Kelo­nia Ther­a­peu­tics to de­vel­op in vi­vo cell ther­a­pies to treat can­cer, but with a twist.

Not on­ly would the treat­ments be off-the-shelf, mean­ing that they would not have to be tai­lored to each pa­tient as cur­rent CAR-T ther­a­pies are, but the two com­pa­nies plan to en­gi­neer them to be “con­vert­ible” — the CAR-T cells could be turned on and off us­ing an an­ti­body.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER